Navigation Links
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Date:5/21/2008

ommercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the ongoing clinical testing of voreloxin, potential safety and efficacy and commercial potential of voreloxin, planned additional clinical testing and development efforts, the timing of enrollment of patients in the company's clinical trials, the adoption of voreloxin as a nonproprietary name and the announcement of clinical results. Words such as "expect," "will," "opportunity," "plans," "could," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk tha
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
3. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
4. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
5. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
6. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
7. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
10. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
11. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... Market Monitor : Global Chiral Separation Columns Market" ... chromatography is a technique involving two enantiomers of the ... consisting of a single enantiomer, thus possessing different elution ... such as cellulose. The chiral separation chromatography ...
(Date:9/18/2014)... Research and Markets has announced ... Investment Report, 2014-2016" report to their offering. ... in percutaneous coronary intervention (PCI), serves not only as ... device for pre-/post-stent dilatations. Therefore, the development of PTCA ... As national economy develops and people,s living ...
(Date:9/18/2014)... , Sept. 18, 2014 It,s ... innovation, increasing clinical development costs, new technologies and ... environment are important factors driving industry change. These ... costs continue to rise due to a lack ... by industry think tanks suggest each day of ...
Breaking Medicine Technology:Micro Market Monitor: Global Chiral Separation Columns Market 2China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... 2011 ,   - ... Aims to Improve Overall Interdisciplinary Care , and Transform Patient ... CPM Resource Center (CPM), a leader in developing,clinical decision support ... Services, a not-for-profit,health system committed to providing services to communities ...
... GROVE, Calif., July 19, 2011 HYCOR Biomedical, Inc., a ... announced that Sean-Xavier Neath, M.D., Ph.D., has been appointed as ... support the company as it works to expand its product ... are pleased to welcome Dr. Neath to the HYCOR team ...
Cached Medicine Technology:Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 2Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 3Elsevier CPM Resource Center to Integrate Evidence-Based Clinical Content Software at Providence Health & Services 4HYCOR Appoints Sean-Xavier Neath as Chief Medical Officer to Support Expansion of Product Lines and Enhance Customer Support Offerings 2
(Date:9/18/2014)... September 18, 2014 Thousands of college ... recognizing their shared fundraising impact on 127 member ... , The first-ever Dance Marathon Day will officially kick ... projected to be raised by college and high school ... Donations generated through Dance Marathon campus programs help provide ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... The National Institutes of Health (NIH) recently awarded ... million grant to the Los Angeles Biomedical Research Institute ... of a vaccine to protect patients from the healthcare-related ... (MRSA). , The National Institute of Allergy ... grant to LA BioMed infectious disease specialists John E. ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ChopChop ... Chef Bill Yosses and Yonah Kalikow, 10-year-old Massachusetts’s winner of ... a twist on hummus, the classic Middle Eastern bean dip. ... on stage how kids can create their own healthy dips ... AM at the third annual Let’s Talk About Food ...
(Date:9/18/2014)... Fla., and DENVER (PRWEB) September 18, 2014 ... in Orlando. This new office, managed by Todd Varney ... health systems in the southeast with the benefits and ... sacrificing the knowledge and advantage of local project delivery ... offices, NexCore has expanded its presence across the country ...
Breaking Medicine News(10 mins):Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3Health News:NexCore Group Opens Regional Office in Orlando, Florida 2
... Battlefield experience linked to hypertension years later, study finds ... in Iraq and Afghanistan who go into combat are ... long term than those who serve in supporting roles, ... combat exposures appeared to be a unique risk factor ...
... obesity rates have reversed gains, study finds , MONDAY, Sept. ... disease may be on the wane, experts say, with a ... now in the clear when it comes to heart disease ... much of the blame for the downturn, the researchers added. ...
... chances of other cancers, clots , MONDAY, Sept. 14 ... risk for developing breast cancer do reduce their cancer ... new analysis suggests. , That was the conclusion of ... clinical trials and a head-to-head assessment of the medications ...
... ... ... American Association of Radon Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , ... ,One St. Louis Union Station, , ,WHY: Radon remains a serious, global health ...
... , , FARMINGDALE, N.Y., Sept. 14 ... minimally invasive ultrasonic medical device technology, which in Europe is ... acute health conditions, has announced that a patient, who wishes ... for Christus St. Vincent Medical Center, Santa Fe, NM, to ...
... LOS ALTOS, Calif., Sept. 14 InteKrin Therapeutics ... has been named Chief Operating Officer. ... Chief Scientific Officer after joining the Company earlier that year. ... increasingly broad operational and strategic responsibility in key areas including ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
Polygraf ID Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: